YAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting (original) (raw)
The YAP/TAZ Signaling Pathway in the Tumor Microenvironment and Carcinogenesis: Current Knowledge and Therapeutic Promises
Ivana Vera
International Journal of Molecular Sciences, 2021
View PDFchevron_right
Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance
Sung Soo Jung
Biochemical and biophysical research communications, 2016
View PDFchevron_right
The Hippo Pathway Effectors YAP/TAZ-TEAD Oncoproteins as Emerging Therapeutic Targets in the Tumor Microenvironment
Myron Szewczuk
Cancers
View PDFchevron_right
TAZ is a novel oncogene in non-small cell lung cancer
Leda Raptis
Oncogene, 2011
View PDFchevron_right
The Hippo pathway effector YAP inhibits HIF2 signaling and ccRCC tumor growth
shu zhuo
Cell Discovery
View PDFchevron_right
YAP promotes erlotinib resistance in human non-small cell lung cancer cells
Zhidong Xu
Oncotarget, 2016
View PDFchevron_right
The Hippo Pathway and YAP/TAZ-TEAD Protein–Protein Interaction as Targets for Regenerative Medicine and Cancer Treatment
Stefania Ferrari
Journal of Medicinal Chemistry, 2015
View PDFchevron_right
Hippo inactivation feeds tumor-initiating cells
Adrian Britschgi
Breast Cancer Research, 2012
View PDFchevron_right
Molecular Pathways: YAP and TAZ Take Center Stage in Organ Growth and Tumorigenesis
Michelangelo Cordenonsi
Clinical Cancer Research, 2013
View PDFchevron_right
Convergence of YAP/TAZ, TEAD and TP63 activity is associated with bronchial premalignant severity and progression
Sarah Mazzilli
Journal of Experimental & Clinical Cancer Research
View PDFchevron_right
YAP1 acts as a negative regulator of pro-tumor TAZ expression in esophageal squamous cell carcinoma
Li-Wha Wu
Cellular Oncology
View PDFchevron_right
Inhibition of yes-associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model
Zhidong Xu
Journal of cellular and molecular medicine, 2018
View PDFchevron_right
YAP/TAZ at the Roots of Cancer
Michelangelo Cordenonsi
Cancer Cell, 2016
View PDFchevron_right
CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis
Daisuke Matsubara
View PDFchevron_right
Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine
Olivier Venier
Cells, 2021
View PDFchevron_right
A feed forward loop enforces YAP/TAZ signaling during tumorigenesis
Shawn Xiong
Nature communications, 2018
View PDFchevron_right
The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene
Elena Takano, Stephen Fox
Oncogene, 2011
View PDFchevron_right
Synthetic molecules targeting yes associated protein activity as chemotherapeutics against cancer
Faiza Rao, Ramsha Iftikhar
Review article, 2021
View PDFchevron_right
The PDZ-binding motif of Yes-associated protein is required for its co-activation of TEAD-mediated CTGF transcription and oncogenic cell transforming activity
Jun Hirayama
Biochemical and Biophysical Research Communications, 2014
View PDFchevron_right
TAZ is an independent prognostic factor in non-small cell lung carcinoma: Elucidation at protein level
Showkat Malik
Cancer Biomarkers, 2017
View PDFchevron_right
LncRNA SFTA1P mediates positive feedback regulation of the Hippo-YAP/TAZ signaling pathway in non-small cell lung cancer
Ramanuj Dasgupta
Cell Death Discovery
View PDFchevron_right
Assays Used for Discovering Small Molecule Inhibitors of YAP Activity in Cancers
Subhajit Maity
Cancers, 2022
View PDFchevron_right
YAP/TAZ and EZH2 synergize to impair tumor suppressor activity of TGFBR2 in non-small cell lung cancer
Sabrina Strano
2020
View PDFchevron_right
Targeting the Hippo signalling pathway for cancer treatment
Hideru Togashi
Journal of biochemistry, 2016
View PDFchevron_right
Hippo in Gastric Cancer: From Signalling to Therapy
Christine Varon
Cancers
View PDFchevron_right
Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene
Thomas Wheeler
Cancer Research, 2010
View PDFchevron_right
The Hippo pathway in normal development and cancer
Ruggero De Maria
Pharmacology & therapeutics, 2018
View PDFchevron_right
Cysteine residues are essential for dimerization of Hippo pathway components YAP2L and TAZ
prem khanal
Scientific Reports, 2018
View PDFchevron_right
Prevalence of the Hippo Effectors YAP1/TAZ in Tumors of Soft Tissue and Bone
Thomas Simmet
Scientific Reports, 2019
View PDFchevron_right
YAP and TAZ: a signalling hub of the tumour microenvironment
Michelangelo Cordenonsi
Nature Reviews Cancer, 2019
View PDFchevron_right
A gain-of-functional screen identifies the Hippo pathway as a central mediator of receptor tyrosine kinases during tumorigenesis
Ta Ha A Zad
View PDFchevron_right
Data from Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene
Scott Goode
View PDFchevron_right
Mutant p53 Protein and the Hippo Transducers YAP and TAZ: A Critical Oncogenic Node in Human Cancers
Maria Ferraiuolo
International journal of molecular sciences, 2017
View PDFchevron_right
Molecular Pathways: Hippo Signaling, a Critical Tumor Suppressor
Heinz-josef Lenz
Clinical cancer research : an official journal of the American Association for Cancer Research, 2015
View PDFchevron_right